EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Efficacy of dolutegravir + lamivudine q.d. with food in people with TB / HIV using a rifampicin‐based regimen: A retrospective observational case series

Yanyun Dou iD, Ruichao Lu, Lingsong Su, Ke Lan, Zhihao Meng, Shanfang Qin, Liling Huang, Wei Huang, Yuanlong Xu, Yu Lv, Yuhong Wen, Shuanglai Lan und 2 weitere

HIV Medicine · 2024

DOI: 10.1111/hiv.13632 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift HIV Medicine, 2024. Verfasst von Yanyun Dou und 13 weiteren Autor:innen. Beteiligte Einrichtung: Chest Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, China. Hauptthemen laut MEDLINE: Lamivudine, Oxazines, Heterocyclic Compounds, 3-Ring, Pyridones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Liuzhou Science and Technology Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Dolutegravir + lamivudine (DTG + 3TC) is a first‐line regimen for people with HIV. However, there are still concerns about its efficacy in people with tuberculosis (TB)/HIV due to the lack of available evidence and drug–drug interaction with rifampicin.

Methods

A single‐centre retrospective observational case series was conducted in Guangxi Zhuang Autonomous Region, China. We included all people with TB/HIV on combined use of once‐daily (q.d.) dosing DTG + 3TC and rifampicin (RIF)‐containing anti‐TB regimens between 2020 and 2022. HIV‐RNA, CD4 cell counts were collected and analysed.

Results

In all, 21 people with HIV (PWH) were included in this study. All the PWH were treatment‐naïve and told to take DTG + 3TC q.d. with food. The median age was 53 years, and 71.43% were male. A total of 71.43% PWH had baseline viral load (VL) > 100 000 copies/mL, and 33.33% had baseline VL greater than 500 000 copies/mL. Only one PWH had CD4 cell count greater than 200 cells/μL, and the median CD4 count was 20 cells/μL. A total of 16 PWH started DTG + 3TC after initiation of the RIF‐based anti‐TB regimen, and the other five PWH initiated DTG + 3TC before the treatment of TB. All the PWH had at least 24 weeks of follow‐up visits and all of the TB treatments were successful. A total of 20 PWH (95.24%) achieved viral suppression (VL

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LamivudineOxazinesHeterocyclic Compounds, 3-RingPyridonesRifampinHIV InfectionsTuberculosisViral LoadHumansMaleRetrospective StudiesFemaleMiddle AgedAdultCD4 Lymphocyte CountChinaPiperazinesAnti-HIV AgentsTreatment OutcomeDrug Therapy, CombinationAntitubercular AgentsDolutegravir

Stichwörter der Autor:innen

HIVdolutegravirlamivudinerifampicintuberculosis

Substanzen

LamivudineOxazinesHeterocyclic Compounds, 3-RingPyridonesRifampinPiperazinesAnti-HIV AgentsAntitubercular AgentsDolutegravir

Autor:innen und Institutionen

  • Chest Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, China.

ORCID-Profile: Yanyun Dou

Förderung

  • Liuzhou Science and Technology Program

Zitieren

APA

Dou, Y., Lu, R., Su, L., Lan, K., Meng, Z., Qin, S., Huang, L., Huang, W., Xu, Y., Lv, Y., Wen, Y., Lan, S., Zuo, Y., & Zhang, Y. (2024). Efficacy of dolutegravir + lamivudine q.d. with food in people with TB / HIV using a rifampicin‐based regimen: A retrospective observational case series. HIV Medicine. https://doi.org/10.1111/hiv.13632

Vancouver

Dou Y, Lu R, Su L, Lan K, Meng Z, Qin S, et al. Efficacy of dolutegravir + lamivudine q.d. with food in people with TB / HIV using a rifampicin‐based regimen: A retrospective observational case series. HIV Medicine. 2024. doi:10.1111/hiv.13632

BibTeX
@article{Dou2024,
  author = {Dou, Yanyun and Lu, Ruichao and Su, Lingsong and Lan, Ke and Meng, Zhihao and Qin, Shanfang and Huang, Liling and Huang, Wei and Xu, Yuanlong and Lv, Yu and Wen, Yuhong and Lan, Shuanglai and Zuo, Yong and Zhang, Yong},
  title = {Efficacy of dolutegravir + lamivudine q.d. with food in people with TB / HIV using a rifampicin‐based regimen: A retrospective observational case series},
  journal = {HIV Medicine},
  year = {2024},
  doi = {10.1111/hiv.13632}
}
Kostenlos starten →